In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

One-year outcomes of elderly patients with atrial fibrillation: snapshot data from the global noninterventional program on edoxaban treatment in routine clinical practice in atrial fibrillation

Session Poster Session 5

Speaker Associate Professor Chun-Chieh Wang

Event : ESC Congress 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Oral Anticoagulation
  • Session type : Poster Session

Authors : CC Wang (Taipei,TW), YH Kim (Seoul,KR), B Brueggenjuergen (Berlin,DE), R De Caterina (Pisa,IT), P Kirchhof (Birmingham,GB), BC Lee (Anyang-Si, Gyeonggi-Do,KR), P Levy (Paris,FR), H Rauer (Munich,DE), PE Reimitz (Munich,DE), M Unverdorben (Basking Ridge,US), T Yamashita (Tokyo,JP), Y Koretsune (Osaka,JP)

C.C. Wang1 , Y.H. Kim2 , B. Brueggenjuergen3 , R. De Caterina4 , P. Kirchhof5 , B.C. Lee6 , P. Levy7 , H. Rauer8 , P.E. Reimitz8 , M. Unverdorben9 , T. Yamashita10 , Y. Koretsune11 , 1Chang Gung University, Department of Cardiology - Taipei - Taiwan , 2Korea University College of Medicine, Department of Internal Medicine - Seoul - Korea (Republic of) , 3Steinbeis-University, Head Institute for Health Economics - Berlin - Germany , 4University of Pisa, Chair of Cardiology - Pisa - Italy , 5University of Birmingham, Institute of Cardiovascular Sciences - Birmingham - United Kingdom , 6Hallym University Sacred Heart Hospital - Anyang-Si, Gyeonggi-Do - Korea (Republic of) , 7Universite Paris-Dauphine - Paris - France , 8Daiichi Sankyo Europe GmbH - Munich - Germany , 9Daiichi Sankyo, Inc - Basking Ridge - United States of America , 10Cardiovascular Institute - Tokyo - Japan , 11National Hospital Organization Osaka National Hospital - Osaka - Japan ,

Oral Anticoagulation

European Heart Journal ( 2019 ) 40 ( Supplement ), 2992

Background: As populations age, prevalence of atrial fibrillation (AF) and ensuing need for oral anticoagulation increase. Benefits and risks of nonvitamin K antagonist oral anticoagulants such as edoxaban in the frail, elderly population with AF in regular clinical care is of special interest.

Purpose: Data from Global ETNA-AF capturing almost 20000 patients treated with edoxaban in Europe, Japan, and Korea/Taiwan, was analyzed to compare outcomes in patients <75 years, elderly (≥75 years), and very elderly (≥85 years) patients.

Methods: Global ETNA-AF is a multinational, multicentre, prospective, noninterventional program (EU: NCT02944019, Japan: UMIN000017011, Korea/Taiwan: NCT02951039). Demographics, baseline characteristics, and 1-year outcome data were reported for 19416 patients classified into 3 age categories.

Results: At 1-year follow-up, rates of major bleeding (including intracranial haemorrhage [ICH]) and ischaemic stroke were generally low. All-cause and CV mortality increased with age; CV mortality was a minor proportion of all-cause mortality in all age groups. Rates of major bleeding and ischaemic stroke increased slightly with age, but to a lesser extent than all-cause and CV mortality. There was no increase in the rate of ICH with age.

Conclusion: Global data from this set of unselected patients support the use of edoxaban as a safe and effective treatment in elderly and very elderly patients with AF in regular clinical care.

<75 yrs (N=9725)≥75 yrs (N=9687)≥85 yrs (N=2186)
Age, median (IQR)68.0 (63.0, 72.0)80.0 (77.0, 84.0)87.0 (86.0, 89.0)
Gender, male %65.851.541.4
BMI, median (IQR)25.6 (22.9, 29.0)24.5 (21.9, 27.5)23.4 (20.8, 26.1)
Weight, median (IQR) kg71.0 (60.0, 84.5)62.5 (52.9, 75.0)55.4 (47.6, 67.0)
CHA2DS2-VASc, mean (SD)2.4 (1.28)4.1 (1.27)4.4 (1.34)
CrCl [mL/min], median (IQR)78.4 (63.6, 95.9)52.0 (41.1, 64.5)40.3 (32.2, 49.4)
Edoxaban 60/30 mg, %64.0/36.034.3/65.715.8/84.2
1-year outcome, n (%/year)
  Major bleeding (ISTH)57 (0.71)93 (1.19)25 (1.53)
  Intracranial hemorrhage22 (0.27)22 (0.28)3 (0.18)
  Major GI* bleeding18 (0.22)36 (0.46)16 (0.98)
  CRNMB**126 (1.57)212 (2.73)56 (3.45)
  Ischaemic stroke53 (0.66)83 (1.06)23 (1.41)
  All-cause/CV mortality95 (1.18)/25 (0.31)224 (2.86)/55 (0.70)89 (5.44)/23 (1.41)
*Gastrointestinal. **Clinically relevant nonmajor bleeding.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are